The 7 analysts offering 12-month price forecasts for Y-mAbs Therapeutics, Inc have a median target of 39.00, with a high estimate of 41.00 and a low estimate of 35.00. The median estimate represents a +18.29% increase from the last price of 32.97.
The current consensus among 8 polled investment analysts is to Buy stock in Y-mAbs Therapeutics, Inc. This rating has held steady since December, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.66
Reporting Date Mar 20
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.